drugset / Trial / NCT03109652

Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients

NCT03109652 ↗

Phase 4 Unknown 144 enrolled Seoul National University Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The usefulness of tranexamic acid(TXA) to reduce blood loss and transfusion in total knee replacement arthroplasty(TKRA) has been demonstrated. However, the optimal does, duration of treatment and route of administration of TXA to reduce blood loss while minimizing adverse effects remain uncertain. Recently, the serial use of perioperative IV and post-operative oral TXA has been shown to significantly reduce transfusion rate without increasing thromboembolic complications compared to placebo. The aim of this study is to 1) determine the beneficial effect and safety of the serial treatment of IV and oral TXA over IV use alone and 2) assess the sufficient length of postoperative use of oral TXA in TKRA patients.

Timeline

Start
2017-07-10
Primary completion
2019-02
Completion
2019-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 500 mg/ml Intravenous
Subject Tranexamic Acid Small molecule 500 mg Intravenous

Indications